Merck KGaA（MRK）株式概要
Merck KGaAはドイツの科学技術企業である。 詳細
報酬
リスク分析
リスクチェックの結果、MRK 、リスクは検出されなかった。
MRK Community Fair Values
Create NarrativeSee what 75 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merck KGaA 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €139.60 |
| 52週高値 | €148.65 |
| 52週安値 | €100.70 |
| ベータ | 0.83 |
| 1ヶ月の変化 | 1.05% |
| 3ヶ月変化 | 24.81% |
| 1年変化 | 21.97% |
| 3年間の変化 | -6.21% |
| 5年間の変化 | -18.39% |
| IPOからの変化 | 800.12% |
最新ニュース
ナラティブの更新 • Jul 06
MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside
Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.ナラティブの更新 • Jun 22
MRK: Life Science Tools Recovery Will Support Future Upside Potential
Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.Recent updates
ナラティブの更新 • Jul 06
MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside
Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.ナラティブの更新 • Jun 22
MRK: Life Science Tools Recovery Will Support Future Upside Potential
Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.ナラティブの更新 • Jun 06
MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside
Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.
ナラティブの更新 • May 23
MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside
Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.ナラティブの更新 • Apr 30
MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside
The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
ナラティブの更新 • Apr 15
MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance
Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.ナラティブの更新 • Apr 01
MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside
Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.ナラティブの更新 • Mar 18
MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside
Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.ナラティブの更新 • Mar 04
MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside
Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.ナラティブの更新 • Feb 18
MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential
Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.ナラティブの更新 • Feb 03
MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential
Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.ナラティブの更新 • Jan 20
MRK: Refined Earnings Outlook Points To Balanced Future Return Potential
Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.ナラティブの更新 • Jan 06
MRK: Future Earnings Power And HPC Expansion May Support Upside
Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.ナラティブの更新 • Dec 21
MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead
Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.ナラティブの更新 • Dec 07
MRK: Margin Strength And AI Deal Will Drive Future Upside
Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.ナラティブの更新 • Nov 23
MRK: New Leadership Change And AI Partnership Will Drive Shares Higher
Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.ナラティブの更新 • Nov 03
MRK: Future CEO Appointment Will Support Recovery and Restore Confidence
The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.ナラティブの更新 • Oct 20
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.ナラティブの更新 • Sep 04
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.分析記事 • Jul 24
We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
新しいナラティブ • Nov 24
AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights
Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.株主還元
| MRK | DE Pharmaceuticals | DE 市場 | |
|---|---|---|---|
| 7D | -5.4% | -5.1% | -1.6% |
| 1Y | 22.0% | 42.4% | -1.3% |
業界別リターン: MRK過去 1 年間で42.4 % の収益を上げたGerman Pharmaceuticals業界を下回りました。
リターン対市場: MRK過去 1 年間で-1.3 % の収益を上げたGerman市場を上回りました。
価格変動
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.8% |
安定した株価: MRK 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: MRKの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1668 | 59,077 | Kai Beckmann | www.emdgroup.com |
Merck KGaA はドイツの科学技術企業。ライフサイエンス、ヘルスケア、エレクトロニクスの各分野で事業を展開している。ライフサイエンス部門は、学術研究所、バイオテクノロジー、製薬メーカー、産業部門向けにツール、化学品、機器を提供している。ライフサイエンス事業では、医薬品メーカー向けに、連続バイオプロセスなどのプロセス開発に関する専門知識や技術、検査キットやサービス、試薬やサービス、空気、水、土壌を分析する検査ソリューション、検査やツール、栄養価の検査や品質のばらつきの特定に役立つ製品などを提供している。ヘルスケア部門は、がん、神経・免疫、不妊、内分泌、心血管、糖尿病、甲状腺疾患、多発性硬化症などの治療用の医療用医薬品およびバイオ医薬品、一般医薬品、注射器および疾患モニタリングソフトウェアの発見、開発、製造、販売を行っている。エレクトロニクス分野では、半導体やディスプレイ産業向けの材料や、デリバリーシステムやサービスなどの表面デザイン、化粧品、効果顔料、機能性ソリューションなどの表面ソリューションを供給している。また、頭頸部がん治療薬候補の開発・商業化に関するデビオファーム・インターナショナルSA社、頭頸部がん治療薬候補の開発・製造・商業化に関する江蘇恒瑞医薬有限公司、頭頸部がん治療薬候補の開発・製造・商業化に関する江蘇恒瑞医薬有限公司とインライセンス契約を結んでいる。Ltd.と転移性大腸がん治療薬の開発・製造・商業化に関するライセンス契約を、Abbisko Therapeutics Co Ltd.、腱鞘炎巨細胞腫治療薬候補の開発・商業化に関するアビスコ・セラピューティクス Co.メルクは1668年に設立され、ドイツのダルムシュタットに本社を置いている。Merck KGaAはE. Merck KGの子会社として運営されている。
Merck KGaA 基礎のまとめ
| MRK 基礎統計学 | |
|---|---|
| 時価総額 | €60.69b |
| 収益（TTM） | €2.53b |
| 売上高(TTM) | €20.96b |
24.0x
PER（株価収益率2.9x
P/SレシオMRK は割高か？
公正価値と評価分析を参照収益と収入
| MRK 損益計算書（TTM） | |
|---|---|
| 収益 | €20.96b |
| 売上原価 | €8.61b |
| 売上総利益 | €12.35b |
| その他の費用 | €9.82b |
| 収益 | €2.53b |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 06, 2026
| 一株当たり利益（EPS） | 5.82 |
| グロス・マージン | 58.93% |
| 純利益率 | 12.08% |
| 有利子負債／自己資本比率 | 40.4% |
MRK の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
1.6%
現在の配当利回り38%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/09 04:28 |
| 終値 | 2026/07/09 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Merck KGaA 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。42
| アナリスト | 機関 |
|---|---|
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Charles Pitman | Barclays |